Loading...
Loading...
ALRN| Name | Value |
|---|---|
| Revenues | 134.0K |
| Cost of Revenue | 52.0K |
| Gross Profit | 82.0K |
| Operating Expense | 7,250.0K |
| Operating I/L | -7,302.0K |
| Other Income/Expense | -37.0K |
| Interest Income | 78.0K |
| Pretax | -7,339.0K |
| Income Tax Expense | 581.0K |
| Net Income/Loss | -7,339.0K |
Aileron Therapeutics, Inc. is a clinical stage chemoprotection oncology company focused on developing ALRN-6924, a promising drug candidate currently in various clinical trials for the treatment of solid tumors, lymphoma, peripheral T-cell lymphoma, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS). The company also conducts combination trials of ALRN-6924 with other drugs for enhanced efficacy. Aileron Therapeutics generates revenue through its research and development efforts, as well as through potential future commercialization of ALRN-6924 and any other successful drug candidates in its pipeline.
